@Article{duepublico_mods_00079132,
  author = 	{El Gabry, Mohamed
		and Arends, Sven
		and Shehada, Sharaf-Eldin
		and Lahner, Harald
		and Kamler, Markus
		and Wendt, Daniel
		and Spetsotaki, Konstantina},
  title = 	{Hedinger Syndrome---Lessons Learnt: A Single-Center Experience},
  year = 	{2023},
  month = 	{Oct},
  day = 	{01},
  keywords = 	{Hedinger syndrome; carcinoid heart disease (CD); neuroendocrine tumors (NET); octreotide; tricuspid valve; hemoperfusion},
  abstract = 	{Background: Hedinger syndrome (HS) or carcinoid heart disease (CD) is a rare and challenging manifestation of malignant neuroendocrine tumours (NETs) involving the heart. We aimed to report our experience with surgical strategies and midterm results in HS patients. Methods: Eleven patients (58 {\textpm} 11 (range 41 to 79 years); 5 females) with HS who underwent cardiac surgery in our department between 07/2005 and 05/2023 were analysed. Results: All patients showed a New York Heart Association (NYHA) class III--IV and in all the tricuspid valve (TV) was involved. Four patients received a TV replacement, and three TV reconstruction. Recently, to preserve the geometry and function of the compromised right ventricle (RV), we have applied the TV ``bio-prosthesis in native-valve'' implantation technique with the preservation of the valve apparatus (tricuspid valve implantation: TVI) in four cases. Concomitant procedures included pulmonary valve replacement in four, pulmonary implantation in one, and aortic valve replacement in three cases. To treat RV failure, we adapted a combined TandemHeart®-CytoSorb® haemoperfusion strategy in Patient {\#}10 and venoarterial extracorporeal membrane oxygenation (V-A ECMO) support avoidance, after experiencing an ECMO-induced carcinoid-storm-related death in Patient {\#}8. Mortality at 30 days was 18{\%} (2/11). The median follow up was 2 {\textpm} 2.1 years (range 1 month to 6 years) with an overall mortality during the follow-up period of 72.7{\%} (8/11). Conclusions: HS surgery, despite being a high-risk procedure, can efficiently prolong survival, and represents a safe and feasible procedure. However, patient selection seems to be crucial. Further follow up and larger cohorts are needed.},
  note = 	{<p>The publication of this article was supported by the Publication Fund of the University of Duisburg-Essen.</p>

<p>This research received no funding.</p>},
  note = 	{<p>El Gabry, M.; Arends, S.; Shehada, S.-E.; Lahner, H.; Kamler, M.; Wendt, D.; Spetsotaki, K. Hedinger Syndrome---Lessons Learnt: A Single-Center Experience. <em>J. Cardiovasc. Dev. Dis</em>. 2023, 10, 413. <a href="https://doi.org/10.3390/jcdd10100413"> https://doi.org/10.3390/jcdd10100413 </a></p>

<p>Published: 1 October 2023</p>},
  note = 	{Version of Record / Verlagsversion},
  doi = 	{10.3390/jcdd10100413},
  url = 	{https://duepublico2.uni-due.de/receive/duepublico_mods_00079132},
  url = 	{https://doi.org/10.3390/jcdd10100413},
  file = 	{:https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00081344/J_Cardiovasc_Dev_Dis_2023_10_413.pdf:PDF},
  language = 	{en}
}